Tumour marker levels in patients with chronic heart failure

Basit Öğe Kaydı
dc.authoridDoğan, Abdullah/0000-0002-1533-4906
dc.authorwosidDoğan, Abdullah/HKN-4767-2023
dc.contributor.authorVarol, E
dc.contributor.authorOzaydin, M
dc.contributor.authorDogan, A
dc.contributor.authorKosar, F
dc.date.accessioned2024-08-04T20:14:55Z
dc.date.available2024-08-04T20:14:55Z
dc.date.issued2005
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground Carbohydrate Antigen 125 (CA 125), a marker for ovarian cancer has been reported to increase in relation to the severity of heart failure. Objective: To evaluate the serum levels of CA 125 and other tumour markers, in patients with chronic heart failure. Methods: Blood levels of CA 125 and other tumour markers were determined in 44 heart failure patients (16 males and 28 females; age 66.3 +/- 6.5 years) before and after optimal medical treatment. Levels were also evaluated in 30 healthy volunteers (11 males and 19 females,age 65.7 +/- 9.8 years). The results in the heart failure patients were grouped according to clinical status (New York Heart Association Class). The mean duration of follow-up was 3 +/- 1.5 months. Results: The mean serum level of CA 125 was 81.9 +/- 91 in the patient group and 7.5 +/- 4.8 in control group (p < 0.001). The mean CA 19-9 level in the patient group (16.8 +/- 16.6) was significantly higher than in the control group (4.5 +/- 2.6) (p < 0.001). CA 125 levels increased as the New York Heart Association (NYHA) functional class increased (Class I/II: 17.7 +/- 22.4 U/ml; Class III: 99.6 +/- 92.1 U/ml; Class IV 136.4 +/- 102.8 U/ml; p < 0.05). There were no significant differences in serum CA 125 and other tumour marker levels before and after optimisation of treatment. Significantly higher serum CA 125 levels were found in patients with pericardial effusion (p=0.002) when compared to patients without pericardial effusion. Conclusion: Among the tumour markers evaluated, only CA 125 seems to be specifically related to the presence and severity of heart failure and also the presence of pericardial fluid. Therefore, measurements of CA 125 serum levels might be proposed for the serial assessment of heart failure. Whether CA 125 has a specific biological role in heart failure requires further investigation. (c) 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.en_US
dc.identifier.doi10.1016/j.ejheart.2004.12.008
dc.identifier.endpage843en_US
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.issue5en_US
dc.identifier.pmid15916923en_US
dc.identifier.scopus2-s2.0-23744491703en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage840en_US
dc.identifier.urihttps://doi.org/10.1016/j.ejheart.2004.12.008
dc.identifier.urihttps://hdl.handle.net/11616/94059
dc.identifier.volume7en_US
dc.identifier.wosWOS:000236408500022en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofEuropean Journal of Heart Failureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCA 125en_US
dc.subjectheart failureen_US
dc.subjecttumour markersen_US
dc.titleTumour marker levels in patients with chronic heart failureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu